The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer (NSRHCXCA)
Primary Purpose
Cervical Cancer
Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Nerve sparing radical hysterectomy
Sponsored by
About this trial
This is an interventional treatment trial for Cervical Cancer focused on measuring cervical cancer, nerve sparing radical hysterectomy
Eligibility Criteria
Inclusion Criteria:
- Histologically diagnosed cervical cancer
- FIGO stage IA2-IIA
- Diameter of tumor is less than 4cm on exam
- One of hitological type written below squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
- Age between 18-70
- Performance status; GOG 0-1
- Normal hematological, hepatic, nephrologic function WBC ≥ 4000 cells/mm3 Platelet ≥ 100,000 /mm3 Hemoglobin ≥ 8.0 gm/dL Serum creatinin ≤ 1.3 mg/dL Serum bilirubin ≤ 1.5 mg/dL SBOT/SGPT and Alkaline phoaphatase < normal X 3
- Patient with informed consent
Exclusion creteria:
- Small cell carcinoma
- Unable to perform surgery because of severe underlying medical disease severe heart disease, congestive heart failure/severe pulmonary disease, pulmonary failure/ active bacterial infectio which needs non oral antibiotic therapy/ associated with other severe medical diseases
- Prior chemotherapy or radiotherapy
- Severe bladder funtion abnormality
- Double primary malignant tumor
- Psychiatric problems
- Pregnant or breast feeding status
- Legally unable to participate clinical trial
- When there is a Doctor's decision that patient is unable to participate clinical trial
Sites / Locations
- Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Nerve sparing radical hysterectomy group
Radical hysterectomy group
Arm Description
sparing hypogastric nerve sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
Conventional radical hysterectomy
Outcomes
Primary Outcome Measures
Incidence of bladder dysfunction after surgery
Remove foley catheter and measure the residual urine volume Measure how long it took to be residual urine volume under 50 mL
Secondary Outcome Measures
rectal & anal function after surgery
Sexual function
Quality of life
operative time
amount of bleeding in operation
frequency of blood transfusion
amount of blood transfusion
postoperative complication
time from surgery to return to work
management cost
size of resected parametrial tissue
2year disease free survival
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01893333
Brief Title
The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer
Acronym
NSRHCXCA
Official Title
The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Unknown status
Study Start Date
March 2013 (undefined)
Primary Completion Date
March 2018 (Anticipated)
Study Completion Date
March 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To develope nerve sparing radical hysterectomy for treatment of cervical cancer to minimize the complication of radical hysterectomy and to maximize quality of life and to evaluate the feasibility and efficacy by prospective randomized trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer
Keywords
cervical cancer, nerve sparing radical hysterectomy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
146 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Nerve sparing radical hysterectomy group
Arm Type
Experimental
Arm Description
sparing hypogastric nerve
sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
Arm Title
Radical hysterectomy group
Arm Type
Active Comparator
Arm Description
Conventional radical hysterectomy
Intervention Type
Procedure
Intervention Name(s)
Nerve sparing radical hysterectomy
Intervention Description
Nerve sparing radical hysterectomy
sparing hypogastric nerve
sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
Primary Outcome Measure Information:
Title
Incidence of bladder dysfunction after surgery
Description
Remove foley catheter and measure the residual urine volume Measure how long it took to be residual urine volume under 50 mL
Time Frame
5 days after the surgery
Secondary Outcome Measure Information:
Title
rectal & anal function after surgery
Time Frame
6, 12 months after surgery
Title
Sexual function
Time Frame
6, 12 months after surgery
Title
Quality of life
Time Frame
6, 12 months after surgery
Title
operative time
Time Frame
immediately after surgery
Title
amount of bleeding in operation
Time Frame
immediately after surgery
Title
frequency of blood transfusion
Time Frame
within 1 week after surgery
Title
amount of blood transfusion
Time Frame
within 1 week after surgery
Title
postoperative complication
Time Frame
within 1 month after surgery
Title
time from surgery to return to work
Time Frame
within 1 month after surgery
Title
management cost
Time Frame
within 1 week after surgery
Title
size of resected parametrial tissue
Time Frame
immediately after surgery
Title
2year disease free survival
Time Frame
2 year after treatment
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically diagnosed cervical cancer
FIGO stage IA2-IIA
Diameter of tumor is less than 4cm on exam
One of hitological type written below squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
Age between 18-70
Performance status; GOG 0-1
Normal hematological, hepatic, nephrologic function WBC ≥ 4000 cells/mm3 Platelet ≥ 100,000 /mm3 Hemoglobin ≥ 8.0 gm/dL Serum creatinin ≤ 1.3 mg/dL Serum bilirubin ≤ 1.5 mg/dL SBOT/SGPT and Alkaline phoaphatase < normal X 3
Patient with informed consent
Exclusion creteria:
Small cell carcinoma
Unable to perform surgery because of severe underlying medical disease severe heart disease, congestive heart failure/severe pulmonary disease, pulmonary failure/ active bacterial infectio which needs non oral antibiotic therapy/ associated with other severe medical diseases
Prior chemotherapy or radiotherapy
Severe bladder funtion abnormality
Double primary malignant tumor
Psychiatric problems
Pregnant or breast feeding status
Legally unable to participate clinical trial
When there is a Doctor's decision that patient is unable to participate clinical trial
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Joo-Hyun Nam, M.D., Ph.D.
Phone
82-2-3010-3633
Email
jhnam@amc.seoul.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joo-Hyun Nam, M.D., Ph.D.
Organizational Affiliation
Asan Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joo-Hyun Nam, M.D., Ph.D.
Phone
82-2-3010-3633
Email
jhnam@amc.seoul.kr
12. IPD Sharing Statement
Learn more about this trial
The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer
We'll reach out to this number within 24 hrs